Regenxbio (RGNX) EBIAT (2016 - 2025)
Regenxbio (RGNX) has 12 years of EBIAT data on record, last reported at -$67.1 million in Q4 2025.
- For Q4 2025, EBIAT fell 31.19% year-over-year to -$67.1 million; the TTM value through Dec 2025 reached -$193.9 million, up 14.63%, while the annual FY2025 figure was -$193.9 million, 14.63% up from the prior year.
- EBIAT reached -$67.1 million in Q4 2025 per RGNX's latest filing, down from -$61.9 million in the prior quarter.
- Across five years, EBIAT topped out at $294.0 million in Q4 2021 and bottomed at -$76.7 million in Q1 2022.
- Average EBIAT over 5 years is -$41.8 million, with a median of -$61.9 million recorded in 2023.
- The widest YoY moves for EBIAT: up 735.85% in 2021, down 764.37% in 2021.
- A 5-year view of EBIAT shows it stood at $294.0 million in 2021, then crashed by 120.38% to -$59.9 million in 2022, then fell by 4.93% to -$62.9 million in 2023, then increased by 18.61% to -$51.2 million in 2024, then plummeted by 31.19% to -$67.1 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$67.1 million in Q4 2025, -$61.9 million in Q3 2025, and -$70.9 million in Q2 2025.